PIK3CA genotype and treatment decisions in human epidermal growth factor receptor 2-positive breast cancer

J Clin Oncol. 2015 Apr 20;33(12):1318-21. doi: 10.1200/JCO.2014.59.3160. Epub 2015 Jan 5.

Authors

David W Cescon¹, Philippe L Bedard²

Affiliations

¹ Princess Margaret Cancer Centre, University Health Network, University of Toronto, and Campbell Family Institute for Breast Cancer Research, Toronto, Ontario, Canada.
² Princess Margaret Cancer Centre, University Health Network, University of Toronto, Toronto, Ontario, Canada philippe.bedard@uhn.ca.

PMID: 25559805
DOI: 10.1200/JCO.2014.59.3160

No abstract available

Publication types

Editorial
Comment

MeSH terms

Antibodies, Monoclonal, Humanized / administration & dosage*
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
Breast Neoplasms / drug therapy*
Breast Neoplasms / genetics*
Female
Humans
Mutation*
Phosphatidylinositol 3-Kinases / genetics*
Receptor, ErbB-2 / metabolism*

Substances

Antibodies, Monoclonal, Humanized
Phosphatidylinositol 3-Kinases
Receptor, ErbB-2